Novità scientifiche — 24 Settembre 2026
Aggiornamenti scientifici verificati da MBC. Questa pagina contiene esclusivamente elementi acquisiti da fonti documentali tracciabili dopo il radar scientifico giornaliero. L’AI può indicare termini da controllare, ma il suo testo non viene pubblicato come fonte e non determina conclusioni cliniche.
Le informazioni sono presentate a fini documentali e non costituiscono una raccomandazione terapeutica, una previsione di efficacia o una valutazione di idoneità individuale.
Farmaci e molecole
- Photothermal Reprogramming of In Vivo Protein Corona on Nanoparticles for Enhanced Breast Cancer Nanotherapy. · Agosto 19, 2026
PMID: 42619035 · DOI: 10.1002/smtd.70960
Fonte documentale originale ↗ - Fibrotic mechanobiological microenvironments drive mechano-immune exclusion and immunotherapy resistance in breast cancer: mechanisms, stratification and therapeutic opportunities · Settembre 1, 2026
DOI: 10.1016/j.intimp.2026.117456
Fonte documentale originale ↗ - Deep Learning-based Volumetric Modulated Arc Therapy Dose Prediction with Uncertainty Quantification for Left- and Right-sided Breast Cancer: A Single-institution Feasibility Study · Luglio 1, 2026
DOI: 10.4103/jmp.jmp_147_26
Fonte documentale originale ↗ - Tumor microenvironment modulation: breaking the cross-resistance barrier in breast cancer antibody-drug conjugate therapy—a narrative review · Settembre 1, 2026
DOI: 10.21037/bc-26-0061
Fonte documentale originale ↗ - 102P Spatial transcriptomic profiling of the tumor immune microenvironment in LSD1 inhibitor-based immunotherapy in triple-negative breast cancer using CosMx single-cell imaging · Settembre 1, 2026
DOI: 10.1016/j.esmoop.2026.108486
Fonte documentale originale ↗ - Exceptional Locoregional Pathological Response in Metastatic Triple‐Negative Breast Cancer Treated With Palliative Platinum‐Based Chemotherapy · Settembre 23, 2026
DOI: 10.1002/ccr3.73586
Fonte documentale originale ↗ - AI-driven multi-omics integration in breast cancer: clinical applications, immunotherapy prediction, and translational challenges · Settembre 24, 2026
DOI: 10.3389/fmolb.2026.1875788
Fonte documentale originale ↗
Nuova documentazione
- Editorial Comment: The Clinical Imperative of Race Disaggregation in Asian American Breast Cancer · Settembre 24, 2026
DOI: 10.1245/s10434-026-20607-2
Fonte documentale originale ↗ - Reliability and Validity of the Arabic Version of Shortened Disabilities of the Arm, Shoulder, and Hand Questionnaire (Quick-DASH) in Breast Cancer Survivors · Maggio 24, 2024
DOI: 10.57197/jdr-2024-0056
Fonte documentale originale ↗ - CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer · Dicembre 1, 2025
DOI: 10.1016/j.xcrm.2025.102512
Fonte documentale originale ↗ - G Protein‐Coupled Receptor 68 Promotes the Progression of Triple‐Negative Breast Cancer and Cuproptosis Resistance via the MEK / ERK Signaling Pathway · Settembre 23, 2026
DOI: 10.1096/fj.202600988r
Fonte documentale originale ↗ - Integrating photoacoustic tomography into a multimodal automated breast ultrasound scanner · Novembre 19, 2020
DOI: 10.1117/1.jbo.25.11.116010
Fonte documentale originale ↗ - Dual-emissive, oxygen-sensing boron nanoparticles quantify oxygen consumption rate in breast cancer cells · Novembre 23, 2020
DOI: 10.1117/1.jbo.25.11.116504
Fonte documentale originale ↗ - Rapid assessment of breast tumor margins using deep ultraviolet fluorescence scanning microscopy · Novembre 25, 2020
DOI: 10.1117/1.jbo.25.12.126501
Fonte documentale originale ↗ - A systems toxicology approach integrating network pharmacology, machine learning, and molecular docking reveals multi-target mechanisms of organophosphate pesticides in promoting breast cancer progression · Settembre 1, 2026
DOI: 10.1093/toxres/tfag073
Fonte documentale originale ↗ - Network Pharmacology and Preliminary in Vitro Evaluation of Piper longum in Breast Cancer · Gennaio 1, 2026
DOI: 10.21106/ijtmrph_266_2026
Fonte documentale originale ↗ - CPT1A as a metabolic gatekeeper linking fatty acid oxidation, ferroptosis resistance, and breast cancer stemness · Settembre 24, 2026
DOI: 10.3389/fonc.2026.1959579
Fonte documentale originale ↗ - Preparation of Allyl‐Isothiocyanate‐Loaded Graphene Quantum Dots: Spectroscopical Characterization and Anticancer Potential Against Triple‐Negative Breast Cancer · Giugno 1, 2026
DOI: 10.1002/slct.73669
Fonte documentale originale ↗ - BMI and the risk of axillary fat infiltration in primary cN0 breast cancer patients – a single-centre, small-cohort, retrospective analysis · Settembre 15, 2026
DOI: 10.53301/lw/210967
Fonte documentale originale ↗ - Organelle‐Targeted, ROS‐Gated Prochelators for Inhibition of Triple‐Negative Breast Cancer via Depleting Exchangeable Copper · Agosto 21, 2026
DOI: 10.1002/adhm.71635
Fonte documentale originale ↗ - Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes · Settembre 1, 2026
DOI: 10.1007/s10549-026-08071-8
Fonte documentale originale ↗ - Feasibility of spatial frequency-domain imaging for monitoring palpable breast lesions · Agosto 22, 2017
DOI: 10.1117/1.jbo.22.12.121605
Fonte documentale originale ↗
Biomarcatori e ricerca
- Kumatakenin as a Multi-Target Putative Inhibitor of Breast Cancer: Network Pharmacology, Molecular Docking and MD Simulation Study via AKT1, EGFR and ESR1 · Settembre 1, 2026
DOI: 10.1016/j.jics.2026.103134
Fonte documentale originale ↗ - Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study · Settembre 24, 2026
DOI: 10.1007/s12325-026-03781-3
Fonte documentale originale ↗ - Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024 · Settembre 1, 2026
DOI: 10.1007/s10549-026-08061-w
Fonte documentale originale ↗ - Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018–2024 · Settembre 1, 2026
DOI: 10.1007/s10549-026-08060-x
Fonte documentale originale ↗
Metastasi ossee, vertebrali e radioligandi
- Sono‐Controllable Janus Hydrogel Platform for Sequential Tumor Eradication and Bone Regeneration in Metastatic Breast Cancer · Settembre 4, 2025
DOI: 10.1002/advs.202506386
Fonte documentale originale ↗
Trial e studi clinici
- Synonymous codon usage shapes ERα function through specialized translational programs during breast cancer progression · Settembre 24, 2026
DOI: 10.1038/s41388-026-03991-7
Fonte documentale originale ↗ - Impact of Couple-Based Intimacy Enhancement on Marital Relationships in Breast Cancer Survivors: A Randomized Controlled Trial · Settembre 24, 2026
DOI: 10.53876/001a.129894
Fonte documentale originale ↗ - Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer · Agosto 18, 2026
NCT: NCT03939897
Fonte documentale originale ↗ - Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial · Agosto 17, 2017
DOI: 10.1117/1.jbo.22.12.121604
Fonte documentale originale ↗
Alimentazione e supporto
- Exploring the feasibility of exercise training during (neo)adjuvant chemotherapy in women with early-stage breast cancer: a pilot study examining immune and metabolic outcomes · Settembre 24, 2026
DOI: 10.1007/s00520-026-11179-8
Fonte documentale originale ↗